AR120655A1 - Anticuerpos ampliamente neutralizantes contra vih - Google Patents
Anticuerpos ampliamente neutralizantes contra vihInfo
- Publication number
- AR120655A1 AR120655A1 ARP200103349A ARP200103349A AR120655A1 AR 120655 A1 AR120655 A1 AR 120655A1 AR P200103349 A ARP200103349 A AR P200103349A AR P200103349 A ARP200103349 A AR P200103349A AR 120655 A1 AR120655 A1 AR 120655A1
- Authority
- AR
- Argentina
- Prior art keywords
- binding fragments
- antibodies against
- neutralizing antibodies
- against hiv
- broadly neutralizing
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- AIDS & HIV (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente se refiere a anticuerpos monoclonales humanos o fragmentos de unión a los mismos que están dirigidos contra el sitio de unión CD4 del virus de inmunodeficiencia humana adquirida HIV-1, una composición farmacéutica que comprende dichos anticuerpos monoclonales humanos o fragmentos de unión a los mismos, un kit que comprende dichos anticuerpos o fragmentos de unión a los mismos y los anticuerpos monoclonales o fragmentos de unión a los mismos y la composición farmacéutica y el kit para usar como medicamento, y para tratamiento o prevención de una enfermedad causada por el virus de inmunodeficiencia humana adquirida HIV-1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19212986.4A EP3831848A1 (en) | 2019-12-02 | 2019-12-02 | Broadly neutralizing antibodies against hiv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120655A1 true AR120655A1 (es) | 2022-03-09 |
Family
ID=68766495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200103349A AR120655A1 (es) | 2019-12-02 | 2020-12-02 | Anticuerpos ampliamente neutralizantes contra vih |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP3831848A1 (es) |
| JP (1) | JP2023503724A (es) |
| KR (1) | KR20220107286A (es) |
| CN (1) | CN115023437A (es) |
| AR (1) | AR120655A1 (es) |
| AU (1) | AU2020394818A1 (es) |
| BR (1) | BR112022010826A2 (es) |
| CA (1) | CA3160303A1 (es) |
| MX (1) | MX2022006632A (es) |
| TW (1) | TW202134279A (es) |
| UY (1) | UY38975A (es) |
| WO (1) | WO2021110764A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023218431A1 (en) * | 2022-05-13 | 2023-11-16 | BioNTech SE | Rna compositions targeting hiv |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2753644A1 (en) * | 2011-09-09 | 2014-07-16 | Universiteit Utrecht Holding B.V. | Broadly neutralizing vhh against hiv-1 |
| WO2013142324A1 (en) * | 2012-03-23 | 2013-09-26 | Usa, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
| US10450368B2 (en) * | 2015-03-19 | 2019-10-22 | Duke University | HIV-1 neutralizing antibodies and uses thereof (CD4bs antibodies) |
| CA3091437A1 (en) * | 2018-02-21 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
-
2019
- 2019-12-02 EP EP19212986.4A patent/EP3831848A1/en active Pending
-
2020
- 2020-12-02 BR BR112022010826A patent/BR112022010826A2/pt unknown
- 2020-12-02 JP JP2022558359A patent/JP2023503724A/ja active Pending
- 2020-12-02 UY UY0001038975A patent/UY38975A/es unknown
- 2020-12-02 CN CN202080094762.6A patent/CN115023437A/zh active Pending
- 2020-12-02 EP EP20815843.6A patent/EP4069732A1/en active Pending
- 2020-12-02 TW TW109142371A patent/TW202134279A/zh unknown
- 2020-12-02 AU AU2020394818A patent/AU2020394818A1/en active Pending
- 2020-12-02 MX MX2022006632A patent/MX2022006632A/es unknown
- 2020-12-02 CA CA3160303A patent/CA3160303A1/en active Pending
- 2020-12-02 KR KR1020227022776A patent/KR20220107286A/ko unknown
- 2020-12-02 AR ARP200103349A patent/AR120655A1/es unknown
- 2020-12-02 WO PCT/EP2020/084309 patent/WO2021110764A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202134279A (zh) | 2021-09-16 |
| JP2023503724A (ja) | 2023-01-31 |
| KR20220107286A (ko) | 2022-08-02 |
| CN115023437A (zh) | 2022-09-06 |
| MX2022006632A (es) | 2022-09-07 |
| EP4069732A1 (en) | 2022-10-12 |
| WO2021110764A1 (en) | 2021-06-10 |
| UY38975A (es) | 2021-04-30 |
| BR112022010826A2 (pt) | 2022-08-23 |
| EP3831848A1 (en) | 2021-06-09 |
| CA3160303A1 (en) | 2021-06-10 |
| AU2020394818A1 (en) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37710A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| CY1124756T1 (el) | Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας | |
| CU20150096A7 (es) | Compuestos de amida y composición farmacéutica para el tratamiento de vih | |
| DOP2019000201A (es) | Compuestos inhibidores del vih | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| DOP2021000195A (es) | Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico | |
| CL2017001191A1 (es) | Compuestos derivados de carbamoilpiridona policíclicos; composición farmacéutica que los comprende; y su uso para el tratamiento de una infección de vih en un humano que tiene o se encuentra en riesgo de tener la infección. | |
| BR112017020837A2 (pt) | compostos de carbamoilpiridona policíclicos e seu uso farmacêutico | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| EA201590358A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
| CO6460769A2 (es) | Inhibidores de la replicación viral novedosos | |
| SV2018005682A (es) | Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana | |
| UY36905A (es) | Anticuerpos neutralizantes de poliomavirus | |
| CR20190447A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| DOP2021000062A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana. | |
| CO2021012579A2 (es) | Compuestos útiles en la terapia del vih | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| CL2017000714A1 (es) | Composiciones farmacéuticas de acción prolongada | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| ES2429422R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
| UY38559A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| UY37449A (es) | Anticuerpos anti-chikv y usos de éstos | |
| CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
| CL2021003388A1 (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana |